HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA.

KEYTRUDA® (pembrolizumab) injection, for intravenous use
Initial U.S. Approval: 2014

---RECENT MAJOR CHANGES---
Indications and Usage (1) 03/2021
Dosage and Administration (2) 03/2021
Warnings and Precautions (5) 11/2020

---INDICATIONS AND USAGE---
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:

Melanoma
- for the treatment of patients with unresectable or metastatic melanoma. (1.1)
- for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection. (1.1)

Non-Small Cell Lung Cancer (NSCLC)
- in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. (1.2)
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. (1.2)
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
  - stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
  - metastatic. (1.2, 2.1)
- as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. (1.2, 2.1)

Small Cell Lung Cancer (SCLC)
- for the treatment of patients with metastatic SCLC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.¹ (1.3)

Head and Neck Squamous Cell Cancer (HNSCC)
- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. (1.4)
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. (1.4, 2.1)
- as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. (1.4)

Classical Hodgkin Lymphoma (cHL)
- for the treatment of adult patients with relapsed or refractory cHL. (1.5)
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. (1.5)

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. (1.6)
- Limitations of Use: KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma
- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10] as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.¹ (1.7, 2.1)
- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.7)
- for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. (1.7)

Microsatellite Instability-High or Mismatch Repair Deficient Cancer
- for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
  - solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options,¹ or
  - colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.¹ (1.8, 2.1)
- Limitations of Use: The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)
- for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC). (1.9, 2.1)

Gastric Cancer
- for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as deterimined by an FDA-approved test, with disease progression on or after 2 or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.¹ (1.10, 2.1)

Esophageal Cancer
- for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
  - in combination with platinum- and fluoropyrimidine-based chemotherapy, or
  - as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test (1.11, 2.1).

Cervical Cancer
- for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.¹ (1.12, 2.1)

Hepatocellular Carcinoma (HCC)
- for the treatment of patients with HCC who have been previously treated with sorafenib.¹ (1.13)

Merkel Cell Carcinoma (MCC)
- for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.¹ (1.14)

Renal Cell Carcinoma (RCC)
- in combination with axitinib, for the first-line treatment of patients with advanced RCC. (1.15)

Endometrial Carcinoma
- in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.¹ (1.16)

Tumor Mutational Burden-High (TMB-H) Cancer
- for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high

(TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.\(^1\) (1.17, 2.1)

- Limitations of Use: The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma (cSCC)
- for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation. (1.18)

Triple-Negative Breast Cancer (TNBC)
- in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥10] as determined by an FDA approved test.\(^2\) (1.19, 2.1)

Adult Indications: Additional Dosing Regimen of 400 mg Every 6 Weeks
- for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications.\(^3\) (1.20, 2.2)

\(^1\) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

\(^2\) This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmator trials.

\(^3\) This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.

DOSAGE AND ADMINISTRATION
- Melanoma: 200 mg every 3 weeks or 400 mg every 6 weeks. (2.2)
- NSCLC: 200 mg every 3 weeks or 400 mg every 6 weeks. (2)
- SCLC: 200 mg every 3 weeks or 400 mg every 6 weeks. (2)\(^2\)
- HNSCC: 200 mg every 3 weeks or 400 mg every 6 weeks. (2\(^2\))
- cHL or PMBCL: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. (2\(^2\))
- Urothelial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks. (2)

\(^1\) MSI-H or dMMR Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; \(2 \text{ mg/kg (up to 200 mg)}\) every 3 weeks for pediatrics. (2\(^2\))
- MSI-H or dMMR CRC: 200 mg every 3 weeks or 400 mg every 6 weeks. (2\)^2\)
- Gastric Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. (2$^2$)
- Esophageal Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. (22)
- Cervical Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks. (23)
- HCC: 200 mg every 3 weeks or 400 mg every 6 weeks. (24)
- MCC: 200 mg every 3 weeks or 400 mg every 6 weeks for adults; $2 \text{ mg/kg (up to 200 mg)}\) every 3 weeks for pediatrics. (25)
- RCC: 200 mg every 3 weeks or 400 mg every 6 weeks with axitinib 5 mg orally twice daily. (26)
- Endometrial Carcinoma: 200 mg every 3 weeks or 400 mg every 6 weeks with lenvatinib 20 mg orally once daily for tumors that are not MSI-H or dMMR. (27)
- TMB-H Cancer: 200 mg every 3 weeks or 400 mg every 6 weeks for adults\(^2\); 2 mg/kg (up to 200 mg) every 3 weeks for pediatrics. \(^2\) (28)
- cSCC: 200 mg every 3 weeks or 400 mg every 6 weeks. (29)

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Melanoma

- TNBC: 200 mg every 3 weeks or 400 mg every 6 weeks. (2,2)
- Administer KEYTRUDA as an intravenous infusion over 30 minutes.

DOSAGE FORMS AND STRENGTHS
- Injection: 100 mg/4 mL (25 mg/mL) solution in a single-dose vial (3)

CONTRAINDICATIONS
None. (4)

WARNINGS AND PRECAUTIONS
- Immune-Mediated Adverse Reactions (5.1)
  - Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated nephritis with renal dysfunction, immune-mediated dermatologic adverse reactions, and solid organ transplant rejection.
  - Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.
  - Withhold or permanently discontinue based on severity and type of reaction.
- Infusion-related reactions: Interrupt, slow the rate of infusion, or permanently discontinue KEYTRUDA based on the severity of reaction. (5.2)
- Complications of allogeneic HSCT: Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody. (5.3)
- Treatment of patients with multiple myeloma with a PD-1 or PD-L1 blocking antibody in combination with a thalidomide analogue plus dexamethasone is not recommended outside of controlled clinical trials. (5.4)
- Embryo-Fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective method of contraception. (5.5, 8.1, 8.3)

ADVERSE REACTIONS
Most common adverse reactions (reported in ≥20% of patients) were:
- KEYTRUDA as a single agent: fatigue, musculoskeletal pain, decreased appetite, pruritus, diarrhea, nausea, rash, pyrexia, cough, dyspnea, constipation, pain, and abdominal pain. (6.1)
- KEYTRUDA in combination with chemotherapy: fatigue/asthenia, nausea, constipation, diarrhea, decreased appetite, rash, vomiting, cough, dyspnea, pyrexia, alopecia, peripheral neuropathy, mucosal inflammation, stomatitis, headache, and weight loss. (6.1)
- KEYTRUDA in combination with axitinib: diarrhea, fatigue/asthenia, hypertension, hepatotoxicity, hypothyroidism, decreased appetite, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation. (6.1)
- KEYTRUDA in combination with lenvatinib: fatigue, hypertension, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, weight loss, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plantar erythrodysesthesia, dyspnea, cough, and rash. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

USE IN SPECIFIC POPULATIONS
Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 03/2021

1.2 Non-Small Cell Lung Cancer
1.3 Small Cell Lung Cancer
1.4 Head and Neck Squamous Cell Cancer
1.5 Classical Hodgkin Lymphoma
1.6 Primary Mediastinal Large B-Cell Lymphoma